News

As pharmaceutical companies scale their use of AI across drug safety operations, the Council for International Organizations of Medical Sciences Working Group XIV's now-published guidance sets the bar for what will be required for sustained system validation.

Cardinal Health's Michelle Britt discusses the policy changes needed to secure independent pharmacy's future, from state advocacy wins to giving pharmacists a seat at the table.

TrumpRx has topped 800 drugs since its February launch, but managed care skepticism over real patient savings persists.

Virtual care's pre- and post-visit windows offer pharma marketers a more targeted, attentive audience than physical waiting rooms, new research shows, and most brands aren't capitalizing on it yet.

Vikram Anand explains how connected pharmacovigilance systems improve HCP and patient experiences, and why predictive, AI-driven intake is the next frontier for manufacturers.

Health care's real challenge isn't more data, it's activation. Arcadia's Sandy Leonard on turning real-world evidence into point-of-care action.

Cardinal Health's Michelle Britt discusses how independent pharmacies are expanding clinical services and leaning on distributor partnerships to meet evolving patient and community needs.

AMCP's Adam Colborn discusses survey findings on TrumpRx's six-month performance, examining payer skepticism about pricing claims and pharmacy access hurdles for patients.

EVERSANA's Vikram Anand explains how disconnected PV systems and manual safety processes can create commercial delays after FDA approval.

JD Power's 2026 U.S. Pharmacy Study shows mail-order satisfaction climbing as brick-and-mortar retailers lose customer trust and perceived value.

In this week's Pharma Pulse, Trump nominates Heidi Overton to lead the FDA, EVERSANA expands its AI-powered commercialization platform into medical affairs and market research, Moderna and Merck's personalized mRNA cancer vaccine clears a landmark Phase 3 trial, and IAG Cargo expands its pharma cold chain network into Kuala Lumpur.

Cardinal Health's Michelle Britt discusses the operating costs, cash flow strain and reimbursement pressures facing independent pharmacies, and how owners are diversifying revenue to stay open.

AI-enabled pharmacovigilance is becoming a commercial capability that protects product value and speeds evidence-based market access decisions.

Trump is expected to pick White House aide Dr. Heidi Overton to lead the FDA, pending Senate confirmation, as the agency works to rebuild industry trust.

IAG Cargo has added a Kuala Lumpur station to its Constant Climate network, its 13th in Asia-Pacific, as regional biologics and personalized medicine demand accelerates.

EVERSANA's Vikram Anand breaks down FDA data on complete response letters, showing how gaps in pharmacovigilance and safety readiness, not manufacturing alone, drive costly delays in drug commercialization.

Separating the combination MMR shot into three vaccines would not just change how children are immunized. It would require building three new supply chains from a licensing base that does not yet exist.

Episode 2 of Supply Chain Signal breaks down the July 31 and September 29 Section 232 deadlines and the proposed generics tariff plan, and what they mean for reshoring.

DSCSA verifies package movement, but resilience requires visibility into capacity, quality and sourcing risk.

Patient Advocate Foundation's Amy Niles on faster CMS prior authorization rules, Medicaid work requirements and what shrinking coverage means for patients.

In this week's Pharma Pulse, Eli Lilly sues companies over black-market retatrutide sales, Bristol Myers Squibb commits $2.3 billion to a new Houston manufacturing campus, and FDA opens an assessment of small dispensers' DSCSA tracing capabilities.

Ed Schoonveld examines how AI is reshaping drug pricing and access, from payer decisions to prescribing, and what it means for new drug treatments.

Across pricing, supply chain, and patient support, the playbooks of pharma commercialization are being rewritten at once for a new era.

Adam Colborn explains why affordability and access aren't the same thing for TrumpRx, and how pharmacy participation gaps can leave patients stuck.

Colborn breaks down why most AMCP members don't see TrumpRx as the lowest price option, and what that means for MFN pricing claims.

DTP programs are outpacing regulatory guidance. Chander Viswanathan and Shannon Wiley, JD make the case for compliance-by-design infrastructure over reactive fixes.

Bristol Myers Squibb will build a $2.3 billion modular manufacturing campus in Houston, part of a $40 billion five-year US investment pledge.

AMCP's Adam Colborn breaks down survey findings on how health plans and PBMs view the TrumpRx platform.